A phase I study showed that APG101 treatment significantly improved PFS with patients with GBM compared to standard radiotherapy and temozolomide alone, and hypomethylation of the CpG2 site within the CD95L promoter resulted in improved benefits (132). Here, FASLG is linked to glioblastoma.